FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

FSD Pharma Announces Share Consolidation and Name Change
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
24/7 Market News Publishes Report Covering Functional Beverage Market, Featuring FSD Pharma
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
24/7 Market News Publishes Report Covering Biotech Developments, Featuring FSD Pharma
FSD Pharma Files Amended and Restated Material Change Report
FSD Pharma provides Corporate Update
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.